Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer

Hepato-Gastroenterology

Volumn 46, Issue SUPPL. 1, 1999, Pages 1274-1279

  Ueda, Yuji ^a   Yamagishi, Hisakazu ^a   Tanioka, Yasuhiko ^a   Fujiwara, Hitoshi ^a   Fuji, Nobuaki ^a   Itoh, Tsuyoshi ^a   Fujiki, Hiroshi ^a   Yoshimura, Tetsunori ^a   Takahiro, Oka ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Digestive tract cancer; Hepatic arterial infusion; Interleukin 2

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOEMBRYONIC ANTIGEN; CD4-CD8 RATIO; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HEPATIC ARTERY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0032972981     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Grimm EA, Mazumuder A, Rosenberg SA, et al: Lymphokine-activated killer cell phenomenon lysis of natural killer-resistant fresh solid tumor cells. J Exp Med 1982; 155:1823-1841.
2. Xu X, Xu L, Ding S, et al: Treatment of 23 patients with advanced gastric cancor by intravenously transfer of autologous tumor-infiltrating lymphocytes combined with rIL-2. Clin Med Sci J 1995; 10:185-187.
3. Nakazato H, Koike A, Saji S, et al: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994; 343:1122-1124.
4. Ueda Y, Yamagishi H, Oka T, et al: In vitro induction of LAK cells with PSK. Biotherapy 1991; 5:1123-1127. (In Japanese with English abstract)
5. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981; 47:207-214.
6. Taniguchi T, Matsui H, Fujita T, et al: Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302:305-310.
7. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10:180-199.
8. Tsunoda T, Tanimura H, Yamaue H, et al: Clinical efficacy of adoptive immunotherapy by IL-4 activated tumor infiltrating lymphocytes in patients with advanced cancer. Int. J Clin Oncol 1997; 2:202-207.
9. Okuno K, Takagi H, Nakamura T, et al: Treatment for unresectable hepatoma via selective arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 1986; 58:1001-1006.
10. Hennemann B, Scheibenbogen C, Andreesen R, et al: Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother 1995; 18:19-27.
11. Okuno K, Hirohata K, Yasutomi M, et al: Hepatic arterial infusion of interleukin-2 based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clinical Therapeutics 1993; 15:672-683.
12. Okuno K, Kobayashi S, Yasutomi M, et al: IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs. Surg Today 1996; 26:662-664.
13. Baba K, Akiyoshi T, Arinaga N: The treatment of patients with locally far-advanced and potentially non-resectable esophageal cancer: Immunotherapy in patients with esophageal carcinoma treated with non-curative resection. Gastroenterol Surg 1996; 19:1576-1596. (In Japanese)
14. Shichijo S, Nakao M, Itoh K, et al: A gene encoding antigen peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187:277-288.
15. Fujimoto S, Araki K, Hamazato S, et al: Development of specific immunotherapy for cancer. Human Cell 1992; 5:247-255. (In Japanese with English abstract)
16. Curti BD, Ochoa AC, Powers GC, et al: Phase 1 trial of anti-CD3 stimulated CD4(+) T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol 1998; 16:2752-2760.